The intricate relationship between the kidney and the heart was documented as early as 1836 by Richard Bright,1 who observed cardiac structural changes in patients with advanced kidney disease. Since then, extensive research has solidified the concept of cardiorenal syndrome, clarifying its pathophysiology, therapeutic approaches, and clinical implications. Chronic kidney disease (CKD) significantly elevates the incidence of diabetes, hypertension, and cardiovascular disease. Notably, treatments for CKD, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, also provide cardioprotective benefits, underscoring the interconnected nature of these conditions.
The intricate relationship between the kidney and the heart was documented as early as 1836 by Richard Bright,1 who observed cardiac structural changes in patients with advanced kidney disease. Since then, extensive research has solidified the concept of cardiorenal syndrome, clarifying its pathophysiology, therapeutic approaches, and clinical implications. Chronic kidney disease (CKD) significantly elevates the incidence of diabetes, hypertension, and cardiovascular disease. Notably, treatments for CKD, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, also provide cardioprotective benefits, underscoring the interconnected nature of these conditions.